Form 4: Galectin Therapeutics Officer Khurram Jamil Reports Stock Option and Restricted Stock Unit Grants

Khurram Jamil, Chief Medical Officer of Galectin Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• On January 23, 2025, Khurram Jamil, the Chief Medical Officer of Galectin Therapeutics, Inc., reported the acquisition of 65,000 stock options and 60,000 restricted stock units (RSUs).
• The stock options, granted under the company's 2019 Omnibus Equity Incentive Plan, have an exercise price of $1.23.
• These options vest in four equal installments on June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.
• The RSUs vest 100% on the earlier of December 31, 2025, or the signing of a partnership agreement, and convert into common stock on a one-for-one basis.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice and suggests confidence in the company's future prospects, but it's not a major event on its own.

Positives

• The granting of stock options and RSUs to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule of the options and RSUs incentivizes continued service and performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the options and RSUs.

Industry Context

Stock option and RSU grants are common practice in the biotechnology industry to incentivize key personnel and align their interests with shareholders, particularly in companies focused on long-term drug development.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Galectin Therapeutics.
• Companies such as Madrigal Pharmaceuticals and Viking Therapeutics also utilize stock options and RSUs to incentivize their leadership teams.
• The vesting schedules and exercise prices are generally in line with industry norms, designed to reward long-term value creation.

Stakeholder Impact

• Shareholders may view the grants positively as they align management's interests with long-term value creation.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates